Pharmaceutical composition for treatment of secondary hyperparathyroidism and therapeutic agent for cardiovascular complications associated with treatment of secondary hyperparathyroidism

摘要

An object of the present invention is to provide a pharmaceutical composition for treating secondary hyperparathyroidism that can reduce the induction of cardiovascular complications due to calcification, and to provide a secondary composition in dialysis patients. An object of the present invention is to provide a therapeutic or preventive agent for cardiovascular complications (eg, arteriosclerosis, ischemic heart disease, etc.) due to calcification accompanying the treatment of hyperthyroidism. According to the present invention, a pharmaceutical composition for treating secondary hyperparathyroidism, comprising, as an active ingredient, a vitamin D derivative having no action of inducing cardiovascular complications due to calcification, and 1α, Secondary hyperparathyroidism in dialysis patients containing 3β-dihydroxy-20S- (3-hydroxy-3-methylbutyloxy) -9,10-seco-5,7,10 (19) -pregnatriene as an active ingredient The present invention provides a therapeutic agent for cardiovascular complications due to calcification associated with the treatment of sickness.